ORLANDO — At 12 months, AURN001, an allogenic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, achieved all primary and secondary endpoints in the phase 1/2 CLARA trial, according to a presenter.
“The exciting thing with that trial is that it is now giving us the opportunity to treat patients with corneal edema from endothelial dysfunction without doing a corneal transplant,” William Barry Lee, MD, of Eye Consultants of Atlanta, told Healio. “This study looked at the safety, efficacy and tolerability of using human corneal endothelial cells for the